Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study

lncRNA MIR503HG functioned as a tumor suppressor and inhibited cell proliferation, metastasis and epithelial-mesenchymal transition in bladder cancer

(2019) Feng Qiu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy

(2018) Simeon U Springer et al.   eLife

Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer

(2018) Ricardo Leão et al.   INTERNATIONAL JOURNAL OF CANCER

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

(2018) J. Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

DNA hypermethylation within TERT promoter upregulates TERT expression in cancer

(2018) Donghyun D. Lee et al.   JOURNAL OF CLINICAL INVESTIGATION

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

(2017) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Epidemiology of urothelial carcinoma

(2017) Jun Miyazaki et al.   INTERNATIONAL JOURNAL OF UROLOGY

Bladder cancer

(2017) Oner Sanli et al.   Nature Reviews Disease Primers

Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA

(2016) Fiona S Togneri et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

(2016) Peter A. Humphrey et al.   EUROPEAN UROLOGY

Follow-up in non–muscle-invasive bladder cancer—International Bladder Cancer Network recommendations

(2016) Wassim Kassouf et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up

(2016) Rossana Critelli et al.   Oncotarget

Urinary Biomarkers for Diagnosis of Bladder Cancer

(2015) Roger Chou et al.   ANNALS OF INTERNAL MEDICINE

Epigenetic biomarkers in the blood of patients with urological malignancies

(2015) Jörg Ellinger et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Mutations inTERTpromoter andFGFR3and telomere length in bladder cancer

(2015) Ismail Hosen et al.   INTERNATIONAL JOURNAL OF CANCER

Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer

(2015) Faysal A. Yafi et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR

(2015) Kun Wang et al.   Oncotarget

Low- and high-grade bladder cancer appraisal via serum-based proteomics approach

(2014) Navneeta Bansal et al.   CLINICA CHIMICA ACTA

Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies

(2014) Bernhard Ralla et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

The Health Economics of Bladder Cancer: An Updated Review of the Published Literature

(2014) Christina Yeung et al.   PHARMACOECONOMICS

Telomerase promoter mutations in cancer: an emerging molecular biomarker?

(2014) João Vinagre et al.   VIRCHOWS ARCHIV

Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression

(2014) Hiroaki Kobayashi et al.   BMC Urology

Recurrence of high-risk bladder cancer: A population-based analysis

(2013) Karim Chamie et al.   CANCER

Evaluation of urovysion and cytology for bladder cancer detection

(2013) Haythem Dimashkieh et al.   CANCER CYTOPATHOLOGY

TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine

(2013) I. Kinde et al.   CANCER RESEARCH

Highly prevalentTERTpromoter mutations in bladder cancer and glioblastoma

(2013) Xiaoli Liu et al.   CELL CYCLE

Highly prevalent TERT promoter mutations in aggressive thyroid cancers

(2013) Xiaoli Liu et al.   ENDOCRINE-RELATED CANCER

Telomerase Reverse Transcriptase Gene Promoter Mutations Help Discern the Origin of Urogenital Tumors: A Genomic and Molecular Study

(2013) Song Wu et al.   EUROPEAN UROLOGY

Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome

(2013) Yves Allory et al.   EUROPEAN UROLOGY

Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine

(2013) Carolyn D. Hurst et al.   EUROPEAN UROLOGY

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism

(2013) P. S. Rachakonda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TERT Promoter Mutations in Familial and Sporadic Melanoma

(2013) S. Horn et al.   SCIENCE

Highly Recurrent TERT Promoter Mutations in Human Melanoma

(2013) F. W. Huang et al.   SCIENCE

Gene-based urinary biomarkers for bladder cancer: An unfulfilled promise?

(2013) Nikhil Sapre et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Frequency of TERT promoter mutations in human cancers

(2013) João Vinagre et al.   Nature Communications

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions

(2013) Jean Charles Nault et al.   Nature Communications

KRASmutation is present in a small subset of primary urinary bladder adenocarcinomas

(2012) Riley E Alexander et al.   HISTOPATHOLOGY

FGFR3 Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 Strategies

(2012) Kim E.M. van Kessel et al.   JOURNAL OF UROLOGY

Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition

(2012) Liang Ying et al.   Molecular BioSystems

Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer

(2012) Liang Ying et al.   Molecular BioSystems

FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing

(2012) Isaac Kinde et al.   PLoS One

A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer

(2012) Steve Goodison et al.   PLoS One

Inducing Cell Proliferation Inhibition, Apoptosis, and Motility Reduction by Silencing Long Noncoding Ribonucleic Acid Metastasis-associated Lung Adenocarcinoma Transcript 1 in Urothelial Carcinoma of the Bladder

(2012) Yonghua Han et al.   UROLOGY

Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity

(2011) Ashish M. Kamat et al.   BJU INTERNATIONAL

The FGFR3 Mutation is Related to Favorable pT1 Bladder Cancer

(2011) Bas W.G. van Rhijn et al.   JOURNAL OF UROLOGY

Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

(2011) George J. Netto   Nature Reviews Urology

Current and Emerging Bladder Cancer Urinary Biomarkers

(2011) Justin Parker et al.   TheScientificWorldJOURNAL

Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle-Invasive Bladder Cancer

(2010) T. C. M. Zuiverloon et al.   CLINICAL CANCER RESEARCH

Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events

(2010) Reza R. Serizawa et al.   INTERNATIONAL JOURNAL OF CANCER

Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer

(2010) Arshad A. Pandith et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer

(2009) Makito Miyake et al.   CANCER SCIENCE

Recurrence, Progression, and Follow-Up in Non–Muscle-Invasive Bladder Cancer

(2009) Antoine G. van der Heijden et al.   EUROPEAN UROLOGY SUPPLEMENTS

Bladder cancer

(2009) Donald S Kaufman et al.   LANCET

Bladder Cancer Detection Using FISH (UroVysion Assay)

(2008) Kevin C. Halling et al.   ADVANCES IN ANATOMIC PATHOLOGY

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study

(2008) Maximilian Burger et al.   EUROPEAN UROLOGY

UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion

(2008) Fan Wang et al.   FEBS LETTERS

The development of multiple bladder tumour recurrences in relation to theFGFR3mutation status of the primary tumour

(2008) Lucie C Kompier et al.   JOURNAL OF PATHOLOGY

Detection of tumours of the urinary tract in voided urine

(2008) Ellen C. Zwarthoff   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing

(2008) Tine Hajdinjak   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS